加味安肾汤治疗早中期强直性脊柱炎肾虚督寒证的疗效及对患者血清炎性因子、免疫功能、骨代谢指标的影响

目的 观察加味安肾汤治疗早中期强直性脊柱炎肾虚督寒证的临床疗效及对患者血清炎性因子、免疫功能、骨代谢指标的影响。方法 120例患者随机分为对照组和观察组,各60例。在甲氨蝶呤治疗基础上,对照组口服补肾舒脊颗粒,观察组口服加味安肾汤,疗程均为8周。观察治疗前后两组临床症状 ［综合指数积分（BAS-G）,巴氏强直性脊柱炎活动指数（BASDAI）,加拿大脊柱骨关节研究协会制定的影像学指数（SPARCC）,中医证状积分］,血清炎性因子［肿瘤坏死因子-α（TNF-α）,巨噬细胞移动抑制因子（MIF）,白细胞介素-23（IL-23）］,免疫功能［免疫球蛋白A（IgA）,免疫球蛋白G（IgG）,免疫球蛋白M（IgM）］,骨代谢指标［骨钙素（BGP）,骨形态发生蛋白-2（BMP-2）,骨特异性碱性磷酸酶（BALP）］水平变化情况。观察两组临床疗效、不良反应及随访12个月复发率。结果 研究期间对照组脱落4例,观察组脱落2例。观察组总有效率96.55%（56/58）,明显高于对照组的80.36%（45/56）（χ²=4.827,P<0.05）;观察组随访12个月复发率5.17%（3/58）,明显低于对照组的19.64%（11/56）（χ²=5.187,P<0.05）。与对照组治疗后比较,观察组BAS-G,BASDAI,SPARCC,中医证状积分,TNF-α,MIF,IL-23水平明显降低（P<0.05）,BGP,BMP-2,BALP,IgA,IgG,IgM水平明显升高（P<0.05）。观察组在研究期间不良反应发生率12.07%（7/58）,明显低于对照组的32.14%（18/56）（χ²=4.826,P<0.05）。结论 加味安肾汤可明显改善早中期强直性脊柱炎肾虚督寒证患者的临床症状、血清炎性因子、免疫功能、骨代谢指标,不良反应发生率低。     

直接前方入路全髋关节置换术治疗强直性髋关节炎

目的探讨直接前方入路全髋关节置换术在治疗强直性髋关节炎中的临床效果。 方法回顾性分析2015年10月至2018年10月于福建省立医院行全髋关节置换术的强直性髋关节炎62例(66髋),纳入强直性脊柱炎合并髋关节炎行全髋关节置换的患者,排除脊柱畸形严重患者。根据手术入路分为直接前入路组和后外侧入路组,比较手术切口长度,术中出血量的差异,通过Harris髋关节功能评分、影像学评价两组患者手术效果。计量资料采用t检验,计数资料采用卡方检验。 结果直接前入路组和后外侧入路组在手术切口长度和术中出血量的差异无统计学意义(t＝1.346、1.272,均为P>0.05)。末次随访平均(25±11)个月,所有患者均解除疼痛,恢复髋关节活动功能。直接前入路组Harris评分术前平均(61±14)分,术后平均(97.8±2.9)分。后外侧入路组Harris评分术前平均(59.3±14.3)分,术后平均(97.4±3.3)分。两组组内术后Harris评分均明显高于术前(t＝14.229、14.729, P<0.001),但两组间差异无统计学意义(t ＝0.416, P>0.05)。术后X线片两组均无骨溶解及假体松动等征象,未发生术后并发症。 结论直接前方入路全髋关节置换治疗强直性髋关节炎的临床效果满意。     

动态监测骨代谢标志物在诊治强直性脊柱炎中的意义

目的通过对血清骨代谢指标的动态检测探讨其与强直性脊柱炎(AS)发生发展的相关性,为AS的诊断预后及治疗提供客观依据。方法根据AS患者骶髂关节的病损程度分早期、进展期、晚期3期,选择各50例门诊及住院患者。对照组选择年龄及性别相匹配的50名健康对照者,取患者晨起空腹血样,采用电化学发光免疫(ECLIA)及酶联免疫吸附试验(ELISA)检测骨代谢相关指标:甲状旁腺素(PTH),总Ⅰ型前胶原氨基末端(N端)前肽(tPINP),骨钙素N端中分子片段(N-MID OT),I型胶原C端肽(β-CTX),25-羟基维生素D3[25-(OH)D3],Ⅰ型胶原交联羧基末端肽(ICTP)。对3期各组间数据进行比较及相关分析。结果①AS组血清中NMID OT、25-(OH)D3低于健康对照组,β-CTX、ICTP高于健康对照组,组间比较差异均有统计学意义(P<0.01);tPINP、PTH浓度水平在AS患者组与健康对照组组间无显著差异性(P>0.05)。②AS晚期组血清中N-MID OT、25-(OH)D3低于早期组,组间比较差异具有统计学意义(P<0.05);晚期组β-CTX、ICTP浓度水平高于早期组,组间比较差异均有统计学意义(P<0.05);晚期组与早期组tPINP、PTH在组间差异无统计学意义(P>0.05);随着AS疾病的进展,血清中N-MID OT、25-(OH)D3浓度水平逐渐降低,β-CTX、ICTP浓度水平显著升高。结论血清骨代谢指标在分期不同的AS患者中存在异常,不同指标参与了AS的骨吸收及骨转换过程,可为AS的诊断预后及治疗提供客观依据。     

Two-level pedicle subtraction osteotomy for severe thoracolumbar kyphotic deformity in ankylosing spondylitis

Study design

A retrospective clinical study.

Objective

To evaluate the outcomes of two-level (T12 and L3) pedicle subtraction osteotomy (PSO) for severe thoracolumbar kyphosis in ankylosing spondylitis (AS), and to discuss the surgical strategies of this surgery.

Background

Cases were limited on the results of two-level PSO for correction of severe kyphosis caused by AS, nor on surgical strategies of this type of surgery.

Methods

From March 2006 to December 2010, nine consecutive AS patients with severe kyphotic deformity, underwent T12 and L3 PSOs. Chin-brow vertical angle (CBVA) and radiographic assessments which contain thoracic kyphosis (TK), lumbar lordosis (LL), global kyphosis (GK), and sagittal vertical axis were carefully recorded pre and postoperatively to evaluate the sagittal balance. Intra and postoperative complications were also registered. All patients were asked to fill out Oswestry Disability Index before surgery and at the last follow-up visit.

Results

All nine patients (8M/1F), averaged 41.4 years old (range 35–51 years), were received two-level (T12 and L3) PSO, and were followed up after surgery for a mean of 39.9 months (range 24–68 months). Good cosmetic results were achieved in all patients. Mean correction at two-level PSO was 67.9 ± 5.5°. All CBVA, TK, LL, and GK were changed significantly after surgery (P < 0.05), the mean amount of correction of which were 59.5 ± 13.8, 34.7 ± 3.8, 33.2 ± 2.4, and 54.0 ± 14.8 degrees, respectively, and with a small loss of correction at the last follow-up visit. Sagittal imbalance was significantly improved from 27.3 ± 4.4 to 3.4 ± 0.7 cm postoperatively. Neither mortalities nor any major neurological complications were found. The mean ODI score was significantly improved from 53.4 ± 15.5 before surgery to 8.2 ± 4.7 at the last visit.

Conclusion

The outcomes of follow-up showed that two-level (T12 and L3) PSO can effectively and safely correct severe thoracolumbar kyphosis in AS.     

强直性脊柱炎患者不同部位骨密度精确性比较及临床意义

目的比较强直性脊柱炎（AS）不同部位骨密度（BMD）测量精确性。方法对27例AS均行双能X线吸收法（DEXA）测定BMD,测定并记录腰椎、股骨颈和桡骨远端BMDZ值。记录患者病程,根据病程将患者分为A组（早期组,病程〈10年）和B组（晚期组,病程≥10年）。结果A、B组腰椎BMDZ值比较,差异有统计学意义（P〈0．05）,股骨颈与桡骨远端BMDZ值2组间比较,差异无统计学意义（P〉0．05）。A组腰椎BMD更低,更能反映患者的低骨量状况;B组腰椎BMD增高,股骨颈BMD更能反映患者的低骨量状况。结论在早期AS患者中。腰椎BMD具有更好的精确性,更能准确反映其低骨量状态;但在晚期AS患者,腰椎BMD精确性降低,股骨颈BMD更能准确地反映其低骨量状态。     

坚骨胶囊联合常规方案治疗强直性脊柱炎合并骨质疏松的临床观察

目的:观察坚骨胶囊联合常规方案治疗强直性脊柱炎合并骨质疏松的临床疗效和安全性。方法:90例强直性脊柱炎合并骨质疏松患者按随机数字表法均分为对照组、观察一组和观察二组。对照组患者给予柳氮磺吡啶片1.0 g,口服,bid;塞来昔布胶囊0.2 g,口服,bid。观察一组患者在对照组治疗的基础上给予阿伦磷酸钠70 mg,每周1次。观察二组患者在对照组治疗的基础上给予坚骨胶囊1.75 g,口服,tid。3组患者均以4周为1个疗程,共治疗6个疗程。观察3组患者的临床疗效,治疗前后中医症状积分及体征,实验室指标,疾病活动度指标,骨代谢生化指标,各部位骨密度值和足跟骨强度指数及不良反应发生情况。结果:治疗后观察二组患者总有效率>观察一组>对照组,3组比较差异有统计学意义(P<0.05)。治疗后3组患者中医症状积分、枕墙距、指地距、颌柄距、实验室指标、疾病活动度指标、骨钙素(BGP)、I型前胶原羧基末端前肽(PICP)、双氢嘧啶脱氢酶(DPD)、I型胶原羧基端吡啶并啉交联肽(ICTP)均显著低于同组治疗前,且观察一组、观察二组均低于对照组;胸廓活动度、脊柱前弯受限、脊柱活动度、甲状旁腺素(PTH)、骨碱性磷酸酶(BALP)、各部位骨密度值及足跟骨强度指数均显著高于同组治疗前,且观察一组、观察二组均高于对照组,差异均有统计学意义(P<0.05),但观察一组与观察二组比较差异无统计学意义(P>0.05)。3组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:坚骨胶囊治疗强直性脊柱炎合并骨质疏松疗效显著,安全性较好。     

综合护理干预在强直性脊柱炎患者中的应用效果

目的：探讨系统功能锻炼及心理干预在强直性脊柱炎（AS）中的应用效果。方法将80例AS患者按照抽签方法随机均分为对照组与观察组,分别给予常规护理干预与康复功能锻炼及心理护理干预。比较两组护理干预前后枕墙距、胸廓扩张度、晨僵时间、疼痛评分及心理状况评分。结果两组患者护理干预前后枕墙距、胸廓扩张度、晨僵时间、疼痛评分相比,差异有统计学意义（P〈0.05）,且两组护理干预后上述指标差异,差异有统计学意义（P〈0.05）;两组护理干预后焦虑自评量表（SAS）及抑郁自评量表（SDS）评分均显著低于护理干预前（P〈0.05或0.01）,且观察组护理干预后SAS及SDS评分均显著低于对照组护理干预后（P〈0.05）。结论与常规护理模式相比,系统的指导功能锻炼及心理护理干预在AS患者中的应用效果显著,患者心理状况改善显著,应加以推广及应用。     

The burden of amyloidosis on the gastrointestinal tract of an ankylosing spondylitis patient

We present a 26-year-old man with edema, ascites and bloody diarrhea that later proved to be due to gastrointestinal and renal amyloidosis. Interestingly, he was also diagnosed as having ankylosing spondylitis,-possibly after a delay of 12 years. The obscure diagnosis and challenging treatment of secondary amyloidosis are further discussed.Electronic Supplementary Material Supplementary material (with figures in color) is available in the online version of this article at .Abbreviations AS ankylosing spondylitis